News
News
-
HnH CTC becomes a strategic partner with AstraZeneca! Click for more details.
-
Nonalcoholic Steatohepatitis (NASH) study is now starting recruitment! Click for more details.
-
New Gastric Cancer study started recruitment!! Click for more details
-
Non-Small-Cell Lung Cancer with KRAS G12C mutation (previously treated) - COMPLETED
Gastrointestinal stroma tumors (previously treated with Imatinib) - RECRUITING
KRAS G12C mutation colorectal cancer (previously treated) -COMPLETED
-
Phase III Study Advanced Colorectal Cancer with KRAS G12C Mutation (COMPLETED)
-
Phase III Study of Second Generation ALK Inhibitors for ALK positive NSCLC (Closed)
-
Phase III Study of Immunotherapy for non-EGFR or ALK genomic tumor aberrations NSCLC (CLOSED)
-
-
Phase III Study of Immunotherapy for Locoregional Hepatocellular Carcinoma (CLOSED)
-
Phase III Study of Immunotherapy & Chemotherapy Combination for Advanced Biliary Tract Cancer (CLOSED)
-
Phase III Study of Monoclonal Antibody Therapy for Idiopathic Pulmonary Fibrosis (CLOSED)
-
Phase III Study of Immunotherapy for Hepatocellular Carcinoma (CLOSED)
-
Phase III Study of Target Therapy for Advanced Hepatocellular Carcinoma (CLOSED)
-
Phase III Study for Unresectable Hepatocellular Carcinoma - RECRUITING! (CLOSED)